Daiwa Securities Group Inc. trimmed its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 30.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 8,160 shares of the company’s stock after selling 3,638 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Neurocrine Biosciences were worth $1,114,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC bought a new stake in Neurocrine Biosciences in the fourth quarter valued at $25,000. Brooklyn Investment Group raised its stake in shares of Neurocrine Biosciences by 99.1% during the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 115 shares in the last quarter. Lindbrook Capital LLC raised its stake in shares of Neurocrine Biosciences by 53.5% during the fourth quarter. Lindbrook Capital LLC now owns 373 shares of the company’s stock valued at $51,000 after purchasing an additional 130 shares in the last quarter. R Squared Ltd bought a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at about $61,000. Finally, UMB Bank n.a. raised its stake in shares of Neurocrine Biosciences by 211.6% during the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after purchasing an additional 309 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, Director Kevin Charles Gorman sold 5,844 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total value of $681,936.36. Following the completion of the sale, the director now directly owns 521,618 shares in the company, valued at approximately $60,867,604.42. The trade was a 1.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the sale, the chief executive officer now owns 135,392 shares of the company’s stock, valued at approximately $19,157,968. This trade represents a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 234,269 shares of company stock worth $34,053,879. 4.30% of the stock is currently owned by insiders.
Analyst Ratings Changes
View Our Latest Stock Report on NBIX
Neurocrine Biosciences Price Performance
Shares of Neurocrine Biosciences stock opened at $110.75 on Friday. The firm has a market cap of $11.04 billion, a price-to-earnings ratio of 33.66, a P/E/G ratio of 0.77 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 52-week low of $105.18 and a 52-week high of $157.98. The stock has a 50-day simple moving average of $129.69 and a 200-day simple moving average of $125.69.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. As a group, equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.
Neurocrine Biosciences declared that its Board of Directors has approved a share repurchase program on Friday, February 21st that allows the company to buyback $500.00 million in shares. This buyback authorization allows the company to repurchase up to 4.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See Also
- Five stocks we like better than Neurocrine Biosciences
- Most active stocks: Dollar volume vs share volume
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How is Compound Interest Calculated?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- ESG Stocks, What Investors Should Know
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.